Diabetes drug fights memory loss in mice with Alzheimer’s
Originally developed to treat type 2 diabetes, the triple GLP-1/GIP/glucagon receptor agonist was found to 'significantly reverse memory loss'.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>